SOURCE-LINKED INTELLIGENCE

International Clinical Validation of Radiomics Artificial Intelligence for Breast Cancer Treatment Planning

CORDIS · observation · Publication date unknown

International Clinical Validation of Radiomics Artificial Intelligence for Breast Cancer Treatment Planning Breast cancer is now the most common cancer worldwide, surpassing lung cancer in 2020 for the first time. It is responsible for almost 30% of all cancers in women and current trends show its increasing incidence. Neoadjuvant chemotherapy (NAC) has shown promise in reducing mortality for advanced cases, but the therapy is associated with a high rate of over-treatment, as well as with significant side effects for the patients. For predicting NAC respondents and improving patient selection, artificial intelligence (AI) approaches based on radiomics have shown promising preclinical evidence, but existing studies have mostly focused on evaluating model accuracy, all-too-often in homogeneous populations. RadioVal is the first multi-centre, multi-continental and multi-faceted clinical validation of radiomics-driven estimation of NAC

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

5838576

unit

EUR